Targeting Ribosome Maturation: A Preclinical Strategy for Triple-Negative Breast Cancer

Conference Coverage
09/12/2025 3 min

Listen "Targeting Ribosome Maturation: A Preclinical Strategy for Triple-Negative Breast Cancer "

Descargar episodio Ver en sitio original

Episode Synopsis



Host: Ryan Quigley



Triple-negative breast cancer (TNBC) remains one of the hardest subtypes to treat, with limited options and high relapse rates—so identifying new therapeutic targets is critical. In this AudioAbstract, Ryan Quigley spotlights research presented at the San Antonio Breast Cancer Symposium that implicates ribosome biogenesis as a key vulnerability. Tune in to learn how this approach could inform the next generation of TNBC therapies.

More episodes of the podcast Conference Coverage

Evaluating PARP and ER Targeting in ER+/HER2– Breast Cancer 22/12/2025
From Resistance to Response: Evolving Treatment Pathways in HR+ Breast Cancer 22/12/2025
Tracking Lineage Infidelity in Pediatric B-ALL: New Insights From ASH 16/12/2025
Beyond the Cure: Addressing Psychosocial Needs in Gene Therapy for SCD 10/12/2025
Bridging the Diagnostic Gap: Blood Biomarkers in Alzheimer’s Care 10/12/2025
Modern Era, New Outcomes: Survival Trends in Breast Cancer Brain Metastases 09/12/2025
CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL 08/12/2025
Rethinking Hormones: Testosterone and Estrogen in Women’s Heart Health 21/11/2025
Targeting Vascular KCNQ5 Channels: A Promising Strategy for Blood Pressure Control 21/11/2025
Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control 21/11/2025
© 2003-2026 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA